Mixed Early Phase III Results With Aldeyra’s First-In-Class Dry Eye Candidate
Aldeyra To Initiate Part 2 Of The Adaptive Phase III Study In 2020
The first part of Aldeyra’s Phase III RENEW study of the aldehyde trap candidate, reproxalap, shows positive effects on one of two co-primary endpoints and indicates an induction-maintenance dosing regimen should be used in part 2 of the study, expected to start in the first half of next year.
